IMS Health
Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per visit can play a large role in which region to select.
Figure 1. Cost per visit rate trends, 2008-2010 and 2011-2013.
IMS Health's current analysis demonstrates that the cost per patient visit in the newer, emerging geographies, is growing more rapidly than in more established regions. The established regions (Western Europe, US/Canada, and Australia/New Zealand) have been averaging 8% annual increases from 2011-2013, while grant costs in developing regions (East Asia, Latin America, and Eastern Europe) are growing at two to three times those rates with an average of 23%. Even if these emerging regions are starting off on a lower base as compared to well established regions, the rapid rise in cost in these regions warrant careful consideration in the coming years.
—IMS Health (for more information contact clinicaltrials@us.imshealth.com)
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.